Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia

Peñafiel, Christian Ramos; Carrillo, Irma Olarte; Maldonado, Rafael Cerón; Miranda-Peralta, Enrique; Fuller, Etta Rozen; Ipiña, Juan Julio Kassack; Centeno-Cruz, Federico; Jaloma, Juan Collazo; Martínez, Adolfo

doi:10.4067/s0034-98872018000700846

Cited by 4 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metformin can also enhance the sensitivity to chemotherapeutic drugs by promoting apoptosis and inhibiting the cell cycle. Clinical data show that the recurrence rate of ALL in a metformin combined with chemotherapy group was lower than that in a chemotherapy group and that this treatment improved the survival rate of patients [ 45 ]. Metformin has been shown to enhance the antitumor effect of anthracyclines and reduce growth and survival of ALL cells [ 46 ].…”

Section: Research Progress On Metformin In Different Types Of Leukemiamentioning

confidence: 99%

Research Progress on the Use of Metformin in Leukemia Treatment

Wang,

Wei

2024

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statementMetformin is a first-line drug in the clinical treatment of type 2 diabetes. Its main molecular mechanism involves the activation of adenosine 5′-monophosphate-activated protein kinase (AMPK), which regulates cell energy metabolism. Many clinical studies have shown that metformin can reduce the incidence and mortality of cancer in patients with or without diabetes. In vitro studies also confirmed that metformin can inhibit proliferation, promote apoptosis, and enhance the response of cells to chemical drugs and other anticancer effects on a variety of leukemia cells. In recent years, leukemia has become one of the most common malignant diseases. Although great progress has been made in therapeutic approaches for leukemia, novel drugs and better treatments are still needed to improve the therapeutic efficacy of these treatments. This article reviews the application status and possible mechanism of metformin in the treatment of leukemia to further understand the anticancer mechanism of metformin and expand its clinical application.

show abstract

Section: Research Progress On Metformin In Different Types Of Leukemiamentioning

confidence: 99%

Research Progress on the Use of Metformin in Leukemia Treatment

Wang,

Wei

2024

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

show abstract

Repurposing Metformin in hematologic tumor: State of art

Chen

et al. 2023

Current Problems in Cancer

View full text Add to dashboard Cite

Metformin alters signaling induced crosstalk and homeostasis in the carcinogenesis paradigm “Epistemology of the origin of cancer”

Brücher

Jamall

2019

4open

View full text Add to dashboard Cite

The anti-hyperglycemic drug, Metformin, is effective in treating early stages of diabetes and has been associated with a 37% decrease in cancer incidence. While the precise mechanisms for the anti-cancer effects of Metformin remain to be elucidated, this review shows the multiplicity of its effects on interdicting signaling and crosstalk, anti-inflammatory effects and in restoring homeostasis, which, taken together, go beyond its well-known anti-hyperglycemic effect that serves as the basis for its use in type 2 diabetes. Metformin is much more than a one-trick pony. The recent discovery of several signaling pathways influenced by Metformin appears to have potential value in cancer therapy. Based on what we know at present, Metformin promotes beneficial effects attributed to its anti-inflammatory and anti-fibrotic effects largely demonstrated in vitro. Metformin activates or upregulates while it simultaneously inhibits or downregulates multiple signaling pathways of cell-cycle arrest and apoptosis accompanied by oxidative stress, which are in accordance with the 6-step sequence of carcinogenesis. Furthermore, in vivo studies in laboratory animals and in cancer patients are beginning to address the magnitude of the anti-cancer effects and delineate its anti-cancer effects. In this context, results from prior pancreatic and non-pancreatic cancer trials, which contained a significant proportion of the patient population treated with Metformin, will have to be reexamined in light of the observed anti-cancerous effects to gain additional insights. The detailed exploration of Metformin in the context of the “Disruption of signaling homeostasis induced crosstalk in the carcinogenesis paradigm Epistemology of the origin of cancer” can provide helpful insights into the anti-proliferative mechanisms and could play a relevant role in anti-cancer therapy in the future.

show abstract

Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia

Cited by 4 publications

References 31 publications

Research Progress on the Use of Metformin in Leukemia Treatment

Research Progress on the Use of Metformin in Leukemia Treatment

Repurposing Metformin in hematologic tumor: State of art

Metformin alters signaling induced crosstalk and homeostasis in the carcinogenesis paradigm “Epistemology of the origin of cancer”

Contact Info

Product

Resources

About